Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein levels.105”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
The cited source says what the claim attributes to it.
In the citing paper
“IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 11×
“Transfection of the indicated plasmids into NIH3T3 cells was performed using CaP04, as described previously (28). pM-v-src and pSG5-STAT3β are plasmid vectors expressing v-src and a dominant negative mutant of STAT3, respectively.”
MethodInfluentialSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897 · cited 2×
“Therefore, we used a tyrphostin inhibitor (AG-490) selective for the JAKfamily tyrosine kinases to determine whether inhibition of the pathway upstream of STAT activation would affect apoptosis in LGL leukemia cells (32).”
MethodWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826 · cited 2×
“The degree of binding was determined by electrophoretic analysis on a 5% native polyacrylamide gel as described previously (19, 31).”
BackgroundMethod
Cited by
Items 401–500 of 643
Lapidot, M., Case, A. E., Larios, D., Gandler, H. I., Meng, C., Tošić, I., Weisberg, E., Poitras, M. J., Gokhale, P. C., Paweletz, C. P., et al. (2020) · Cancers · doi:10.3390/cancers13010007 · Cited by 21
“Whereas both drugs led to a significant reduction in BIRC5 expression within this group of cell lines, only pyrimethamine significantly reduced MCL1 expression.”
BackgroundDNA microarray analysis of T cell‐type lymphoproliferative disease of granular lymphocytes
Makishima, H., Ishida, F., Ito, T., Kitano, K., Ueno, S., Ohmine, K., Yamashita, Y., Ota, J., Ôta, M., Yamauchi, K., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03646.x · Cited by 21
“Interestingly, Epling-Burnette et al (2001) have found that STAT3 (signal transducers and activators of transcription, 3) was constitutively activated in LGL cells by an as yet unidentified mechanism, which may partially account for the Fas-resistance in these cells.”
BackgroundUllah, F., Markouli, M., Orland, M. D., Ogbue, O., Dima, D., Omar, N., & Ali, M. K. M. (2024) · Cancers · doi:10.3390/cancers16071307 · Cited by 25
Allergy and risk of hematologic malignancies: Associations and mechanisms
Musolino, C., Allegra, A., Minciullo, P. L., & Gangemi, S. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.08.004 · Cited by 20
Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma
Nakashiro, K. (1994) · Oncology Reports · doi:10.3892/or_00000085 · Cited by 21
Olson, K. C., Moosic, K. B., Jones, M., Larkin, P. M. K., Olson, T. L., Toro, M. F., Fox, T. E., Feith, D. J., & Loughran, T. P. (2020) · Cancer Medicine · doi:10.1002/cam4.3246 · Cited by 20
Self-citationRedell, M. S., Tsimelzon, A. I., Hilsenbeck, S. G., & Tweardy, D. J. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1206766 · Cited by 30
“, Bcl-2, Bcl-XL, Mcl-1) have been reported to be down-regulated and up-regulated, respectively, by Stat3 activation in neoplastic cells [14, 52–54].”
BackgroundWu, J., Feng, X., Zhang, B., Li, J., Xu, X., Liu, J., Wang, X., Wang, J., & Tong, X. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1529-8 · Cited by 20
“It was previously shown that when the JAK pathway was blocked with the inhibitor AG490, the expression of STAT3 target genes was down-regulated and apoptosis was induced in many cancer cell types [26–28].”
BackgroundSelf-citationBleesing, J., Janik, J. E., & Fleisher, T. A. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04034.x · Cited by 20
“…of STAT (signal transducers and activators of transcription) proteins could then provide a link between the current finding of B220 expression and a previous observation of highly increased levels of phosphorylated STAT3 in T-LGL cells, linked to cell survival (Epling-Burnette et al, 2001).”
BackgroundCytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia
Isabelle, C., Boles, A. E., Chakravarti, N., Porcu, P., Brammer, J. E., & Mishra, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.849917 · Cited by 20
“, constitutive STAT3 activation is one of the defining features of the pathogenesis of LGLL (41).”
BackgroundMalayil, R., Chhichholiya, Y., Vasudeva, K., Singh, H. V., Singh, T., Singh, S., & Munshi, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02037-2 · Cited by 20
“Previous studies revealed that inhibition of STAT3 expression provokes cancer cell death by upregulating the proapoptotic protein Fas and downregulating the antiapoptotic Mcl-1 [62].”
BackgroundSignificance of p-STAT3 expression in human colorectal adenocarcinoma
Parkash (1994) · Oncology Reports · doi:10.3892/or_00000047 · Cited by 19
Viny, A. D., Clemente, M. J., Jasek, M., Askar, M. Z., Ishwaran, H., Nowacki, A. S., Zhang, A., & Maciejewski, J. P. (2010) · Haematologica · doi:10.3324/haematol.2010.021865 · Cited by 20
“Median platelet count x10(9)/L (range) 189 (25-751) 194 (8-594) 0.”
Lu, Z., Hong, C. C., Jark, P. C., Assumpção, A. L. F. V., Bollig, N., Kong, G., & Pan, X. (2017) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14837 · Cited by 19
“The link between STAT3 activation and regulation of Bcl-2 family protein expression has been extensively studied in human lymphoid cells.(29,30) STAT3 inhibition is associated with increased apoptosis and decreased Mcl-1 expression in large granular lymphocytic leukemia.”
BackgroundEl-kott, A. F., ElBealy, E. R., Alshehri, A. S., El-Kenawy, A. E.-M., Khalifa, H. S., & Al‐Ramlawy, A. M. (2021) · Cancer Biomarkers · doi:10.3233/cbm-203257 · Cited by 20
Mailloux, A. W., Zhang, L., Moscinski, L. C., Bennett, J. M., Yang, L., Yoder, S., Bloom, G. C., Wei, C., Sheng, W., Sokol, L., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203424 · Cited by 20
“Although a STAT3-activation signature and DNA-binding activity were detected in most LGL leukemia patients (57), the estimated frequency of the Src homology 2 domain mutation is ∼28–40% in both NK and T cell LGL leukemia patients (63, 64), suggesting that this mutation may represent one of multiple mechanisms leading…”
BackgroundSelf-citationYoshida, A., Ookura, M., Zokumasu, K., & Ueda, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.04.002 · Cited by 18
Larkin, P. M. K., Olson, K. C., Hamele, C. E., Toro, M. F., Tan, S., Feith, D. J., & Loughran, T. P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193429 · Cited by 19
“Since STAT1, STAT3, and STAT5 have been shown to transcribe IFN-γ [32–36] and play a role in T-LGLL pathogenesis [23, 37], we chose to focus on these transcription factors in the context of IL-2 supplementation.”
BackgroundSelf-citationLarge Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment
Magnano, L., Rivero, A., & Matutes, E. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01159-y · Cited by 17
Semenzato, G., Calabretto, G., Teramo, A., Gasparini, V. R., Rampazzo, E., Barilà, G., & Zambello, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00977-0 · Cited by 24
“A constitutive activation of the STAT3 signaling pathway has long been demonstrated in T-LGLL [36, 37] and the discovery of STAT mutations [13] has been instrumental in expanding our understanding of LGL leukemogenesis but also in improving the classi fi cation of these disorders [1, 2].”
BackgroundLarge granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations
Marchand, T., Pastoret, C., Moignet, A., Roussel, M., & Lamy, T. (2024) · Hematology · doi:10.1182/hematology.2024000539 · Cited by 17
Are T-LGL leukemia and NK-chronic lymphoproliferative disorder really two distinct diseases?
Zambello, R., Teramo, A., Gattazzo, C., & Semenzato, G. (2014) · Europe PMC (PubMed Central) · doi:10.14273/unisa-227 · Cited by 17
“They also showed that STAT3 activation contributes to Fas resistance resulting in abnormal survival of leukemic LGL and is also responsible of the over-expression of the anti-apoptotic protein Mcl-1 [55].”
BackgroundQiu, Z.-Y., Qin, R., Tian, G., Wang, Y., & Zhang, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s222378 · Cited by 17
“These observations were not limited to the STAT3 mutation(+) patients with LGLLassociated PRCA; similar findings were also recognized in STAT3 mutation(-) patients with LGLL-associated PRCA, but not in normal controls.(98,99) The mechanisms of proliferative and/or anti-apoptotic characteristics of LGLs in STAT3 mutati…”
ResultRecent advances in T-cell lymphoid neoplasms
Bigas, A., Rodríguez‐Sevilla, J. J., Espinosa, L., & Gallardo, F. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.12.191 · Cited by 18
SH2 domain binding to phosphopeptide ligands: potential for drug targeting
Moses, M. K. (2009) · Frontiers in bioscience · doi:10.2741/3292 · Cited by 18
Li, X., Wang, H., Lu, X., & Di, B. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2010.156 · Cited by 17
The role of signal transducer and activator of transcription 3 in Rift Valley fever virus infection
Pinkham, C., An, S., Lundberg, L., Bansal, N., Benedict, A., Narayanan, A., & Kehn‐Hall, K. (2016) · Virology · doi:10.1016/j.virol.2016.06.004 · Cited by 20
“There is increasing evidence that STATs play a role in apoptosis, given that the inhibition of STAT3 induces apoptosis in various cancer cell lines (Aoki et al., 2003; Battle and Frank, 2002; Epling-Burnette et al., 2001).”
BackgroundCHO, S.-D., Yu, H., Park, C., Kim, S., & Cho, N. (2014) · Pharmacognosy Magazine · doi:10.4103/0973-1296.139802 · Cited by 17
“[29‐32] Among them, inhibition of constitutive STAT3 activation in malignant cells can suppress Bcl‐xL or Mcl‐1 genes.[29,30,33,34] We found that CT decreased Mcl‐1 protein levels, but did not alter Bcl‐xL levels in MC‐3 cells.”
BackgroundFukumoto, T., Iwasaki, T., Okada, T., Hashimoto, T., Moon, Y., Sakaguchi, M., Fukami, Y., Nishigori, C., & Oka, M. (2016) · Genes to Cells · doi:10.1111/gtc.12330 · Cited by 17
“It has been shown that Mcl-1 is transcriptionally regulated by signal transducer and activator of transcription 3 (STAT3) (Epling-Burnette et al. 2001; Bhattacharya et al. 2005), whose function is regulated by its phosphorylation at Tyr705 and Ser727 (Wen et al. 1995; Decker & Kovarik 2000;…”
BackgroundT-Cell Large Granular Lymphocytic Leukemia
Zhou, F., & Chan, W. C. (. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7216-0040-6.00030-7 · Cited by 16
Genomics of LGL leukemia and select other rare leukemia/lymphomas
Moosic, K. B., Paila, U., Olson, K. C., Dziewulska, K. H., Wang, T. T., Xing, J. C., Ratan, A., Feith, D. J., Loughran, T. P., & Olson, T. L. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.06.003 · Cited by 16
“Even in the absence of STAT3 mutation, all LGL leukemia patients show constitutively active STAT signaling (36).”
BackgroundSelf-citationJiang, Y., Han, X., Dou, J.-Y., Yuan, M.-H., Zhou, M.-J., Cui, Z., Lian, L., Nan, J., Zhang, X., & Wu, Y. (2022) · Food & Function · doi:10.1039/d1fo04404d · Cited by 16
The androgen receptor mediates antiapoptotic function in myometrial cells
Li, H., Li, Y., Morin, D., Plymate, S. R., Lye, S. J., & Dong, X. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.303 · Cited by 16
“Ligand-activated AR can recruit and activate Src kinase,(34) which in turn enhance the transcriptional activity of STAT3 to upregulate Mcl-1 gene transcription.(35) Other reported pathways that induce Mcl-1 levels in myometrial cells are the NFkB pathway, endoplasmic reticulum stress response and its adaptive unfolded…”
BackgroundSelf-citationSec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells
Tanaka, T., Kikuchi, N., Goto, K., & Iino, M. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1230-9 · Cited by 16
“As the transcription of Bcl-2 or Mcl-1 is controlled by several transcriptional factors, including Myc [34], nuclear factor-kappa B (NF-jB) [35, 36], E2F1 [37], cAMP response element (CRE) [38], and p53 [39, 40], we next evaluated the effect of Sec6 or Sec8 downregulation on transcriptional activity.”
BackgroundZhang, H., Zhang, D., Luan, X., Xie, G., & Pan, X. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800512 · Cited by 17
Nicotine Upregulates the Level of Mcl-1 through STAT3 in H1299 Cells
Zhou, M., Zhao, J., Zhang, Q., Jin, X., Liao, M., Zhang, L., Wang, J., & Yang, M. (2019) · Journal of Cancer · doi:10.7150/jca.35453 · Cited by 16
“Activated STAT3 was shown to bind an SIE-related element of Mcl-1 promoter in large granular lymphocyte (LGL) leukemia [19].”
BackgroundSelf-citationRAI14 silencing suppresses progression of esophageal cancer via the STAT3 pathway
Wang, J., Cai, Y., Luo, J., Sun, Z., Yu, J., Yan, F., & He, X. (2020) · Aging · doi:10.18632/aging.103613 · Cited by 15
“In parallel, the expression levels of Mcl-1 and cyclin D1 were decreased and the level of cleaved caspase-3 was increased in cells that were treated with AG490 as compared with those in cells that were treated with DMSO (Figure 6A).”
BackgroundInfluentialSelf-citationDrillet, G., Pastoret, C., Moignet, A., Lamy, T., & Marchand, T. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.03.014 · Cited by 15
Sasaki, R., Ito, S., Asahi, M., & Ishida, Y. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.10.012 · Cited by 15
Soubh, A. A., El-Gazar, A. A., Mohamed, E. A., Awad, A. S., & El-Abhar, H. S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108123 · Cited by 17
Liu, M., Wang, F., Wen, Z., Shi, M., & Zhang, H. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.861471 · Cited by 15
Jak/Stat Pathway in Waldenström's Macroglobulinemia
Hodge, L. S., & Ansell, S. M. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2011.n.023 · Cited by 15
Klener, P., Anděra, L., Klener, P., Nečas, E., & Živný, J. (2006) · Folia Biologica · doi:10.14712/fb2006052040119 · Cited by 19
Yu, L.-F. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i6.875 · Cited by 15
Vrana, J. A., Cleaveland, E. S., Eastman, A. R., & Craig, R. W. (2006) · APOPTOSIS · doi:10.1007/s10495-006-7787-y · Cited by 16
Natural bioactive compounds and STAT3 against hepatocellular carcinoma: An update
Manoharan, S., Saha, S., Murugesan, K., Santhakumar, A., & Perumal, E. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122351 · Cited by 14
The role of cytokines in the pathogenesis of malignant neoplasms
Львовна, Р. В., Adamova, G. V., & Oslina, D. S. (2023) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20230202 · Cited by 14
Xing, W., Hao, L., Yang, X., Li, F., & Huo, H. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2253 · Cited by 14
Siavash, H., Nikitakis, N. G., & Sauk, J. J. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500505 · Cited by 17
MicroRNA‑4500 suppresses tumor progression in non‑small cell lung cancer by regulating STAT3
Li, Z., ZHANG, Z. W., Bi, H. C., Zhang, Q., Zhang, S., Zhou, L., Zhu, X., & Zhou, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10737 · Cited by 13
RetractedAssi, H. H., Espinosa, J. R., Suprise, S., Sofroniew, M. V., Doherty, R. E., Zamler, D. B., Lowenstein, P. R., & Castro, M. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096318 · Cited by 15
“STAT3 antibody was purchased from Cell Signaling [9 9139].”
Yamamoto, K., Shinomiya, K., Ioroi, T., Hirata, S., Harada, K., Suno, M., Nishioka, T., Kume, M., Makimoto, H., Nakagawa, T., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0382-9 · Cited by 13
“Activation of the protein kinase B and STAT3 pathways has been reported to drive PDL1 expression [23, 24].”
BackgroundSun, X., Hasanali, Z. S., Chen, A., Zhang, D., Liu, X., Wang, H., Feith, D. J., Loughran, T. P., & Xu, K. (2014) · British Journal of Haematology · doi:10.1111/bjh.13143 · Cited by 13
Self-citationSchrenk, K. G., Krokowski, M., Feller, A. C., Bernhard, V., Mügge, L., Oelzner, P., Wolf, G., Hochhaus, A., & Neumann, T. (2013) · Annals of Hematology · doi:10.1007/s00277-012-1649-1 · Cited by 13
The Small Heat Shock Protein 27 Is a Key Regulator of CD8+CD57+ Lymphocyte Survival
Wood, K. L., Voss, O. H., Huang, Q. M., Parihar, A., Mehta, N., Batra, S., & Doseff, A. I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902953 · Cited by 13
“The PI3K and STAT3 pathways have been found to be upregulated in CD8 cells and PBMCs from patients with LGL and play a role in this Fas resistance (37, 38).”
BackgroundPan-Bcl-2 Inhibitor AT-101 Enhances Tumor Cell Killing by EGFR Targeted T Cells
Thakur, A. B., Lum, L. G., Schalk, D. L., Azmi, A. S., Banerjee, S., Sarkar, F. H., & Mohommad, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047520 · Cited by 14
“Constitutive Stat3 activation can lead to resistance to apoptosis [35].”
BackgroundWu, Y., Zhang, Z., & Lian, X. (2025) · Journal of Ginseng Research · doi:10.1016/j.jgr.2025.07.003 · Cited by 12
“Phosphorylation at Y705 is a common activation site, enabling Stat3 to bind directly to the promoter of the anti-apoptotic gene Mcl1 , thereby promoting its transcription [46].”
Ruff, K., Puetter, A., & Levy, L. S. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-35 · Cited by 12
“The STAT3mediated resistance to apoptosis of those cells was independent of Bcl-2 expression [49].”
BackgroundToward a Better Classification System for NK-LGL Disorders
Drillet, G., Pastoret, C., Moignet, A., Lamy, T., & Marchand, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.821382 · Cited by 12
Kornsuthisopon, C., Rochanavibhata, S., Nowwarote, N., Tompkins, K. A., Sukarawan, W., & Osathanon, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158676 · Cited by 12
“The downstream targets of the JAK/STAT pathway include anti-apoptotic protein family members, such as the Bcl-2 family [55].”
BackgroundLyu, M.-A., Sung, B., Cheung, L. H., Marks, J. W., Aggarwal, B. B., Aguiar, R. C. T., & Rosenblum, M. G. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.017 · Cited by 12
Combined RNAi targeting human Stat3 and ADAM9 as gene therapy for non-small cell lung cancer
Chang, L., Gong, F., Cai, H., Li, Z., & Cui, Y. (2015) · Oncology Letters · doi:10.3892/ol.2015.4018 · Cited by 12
RetractedRoders, N., Herr, F., Ambroise, G., Thaunat, O., Portier, A., Vázquez, A., & Dürrbach, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00787 · Cited by 12
Tanahashi, T., Sekiguchi, N., Matsuda, K., Takezawa, Y., Ito, T., Kobayashi, H., Ichikawa, N., Nishina, S., Senoo, N., Sakai, H., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.04.001 · Cited by 12
STAT3 Inhibition Induces Apoptosis in Cancer Cells Independent of STAT1 or STAT2.
Shodeinde, A., Ginjupalli, K., Lewis, H. D., Riaz, S., & Barton, B. E. (2013) · PubMed · Cited by 13
Wang, G., Ren, Z., Wang, P., Su, C., Zhang, W., LIU, Z.-G., Zhang, L., Zhao, X., & Chen, G. (2014) · Oncology Reports · doi:10.3892/or.2014.3233 · Cited by 11
Xu, S., Xu, Z., Liu, B., Sun, Q., Yang, L., Wang, J., Wang, Y., & Liu, H. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.07.004 · Cited by 11
Self-citationChe (2009) · Oncology Reports · doi:10.3892/or_00000448 · Cited by 11
Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's Lymphoma
Bonavida, B., & Vega, M. I. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.02.004 · Cited by 11
Zou, M., Xu, C., Li, H., Zhang, X., & Fan, W. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.07.002 · Cited by 11
RetractedFinn, W. G., & Peterson, L. C. (2004) · Kluwer Academic Publishers eBooks · doi:10.1007/b113185 · Cited by 12
Pleiotropic Action of AP-1 in v-Src-Transformed Cells
Wang, L., Rodrigues, N., Wu, Y., Maślikowski, B. M., Singh, N. N., Lacroix, S., & Bédard, P. (2011) · Journal of Virology · doi:10.1128/jvi.01013-10 · Cited by 11
“Antiapoptotic factors such as BclxL, Bcl-2, NR-13, and Mcl-1 mediate the action of Src, which employs several transcription factors and signaling pathways to stimulate the expression of these proteins in a cell type-specific manner (10, 15, 20, 28, 37, 38, 41, 53, 55).”
BackgroundYu, H., Shin, J., Jung, J., Nam, J., Hong, I., Cho, N., & Cho, S. (2014) · Head & Neck · doi:10.1002/hed.23749 · Cited by 10
“It was recently reported that STAT3 was highly activated in large granular lymphocyte leukemia cell lines and that the STAT3 inactivation by antisense oligonucleotides and a specific inhibitor of JAK2 (AG490) resulted in Mcl-1 inhibition and apoptotic cell death.(17) This suggests that STAT3 may play an important role…”
BackgroundDeveloping an in vitro model of T cell type of large granular lymphocyte leukemia
Ren, T., Yang, J., Broeg, K., Liu, X., Loughran, T. P., & Cheng, H. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.10.002 · Cited by 10
“The primary leukemic cells exhibit constitutive activities of STAT3 and NF-κB, and both factors are critical mediators of oncogenic signaling and survival pathways [12, 13].”
BackgroundSelf-citationYu, Y., Wu, J., Feng, S., Yu, H., Liu, C., & Wang, S. (2024) · Toxicology · doi:10.1016/j.tox.2024.153740 · Cited by 10
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells
Parri, E., Kuusanmäki, H. A., Bulanova, D. R., Mustjoki, S. M., & Wennerberg, K. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003300 · Cited by 10
The Intrinsic Pathway of Apoptosis
Kaufmann, S. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-221-2_1 · Cited by 14
Li, W., Huang, H., Su, J., Ji, X., Zhang, X., Zhang, Z., & Wang, H. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0682-4 · Cited by 10
RetractedLarkin, P. M. K., Olson, K. C., Olson, T. L., Hamele, C. E., Carter, K. N., Feith, D. J., & Loughran, T. P. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.009 · Cited by 9
“T-LGLL cells have constitutively activated STAT1 and STAT3 [6] and T-LGLL patients have significantly elevated serum interferon gamma (IFN-γ) levels [7].”
BackgroundSelf-citationVicenzetto, C., Gasparini, V. R., Barilà, G., Teramo, A., Calabretto, G., Rampazzo, E., Carraro, S., Trimarco, V., Trentin, L., Facco, M., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282306 · Cited by 12
“12 The state of activation of T-LGL clones is sustained either by the gain-of-function mutations frequently found in the Src homologous 2 (SH2) domain of the gene, with Y640F and D661Y being the most recurrent, or by cytokine stimulation.”
BackgroundA lineage-specific STAT5B N642H mouse model to study NK-cell leukemia
Klein, K., Kollmann, S., Hiesinger, A., List, J., Kendler, J., Klampfl, T., Rhandawa, M., Trifinopoulos, J., Maurer, B., Grausenburger, R., et al. (2024) · Blood · doi:10.1182/blood.2023022655 · Cited by 8
Participation of Interferon-Alpha in Regulation of Apoptosis
Бажанова, Е. Д. (2005) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1007/s10893-005-0045-z · Cited by 8
“According to other data, IA leads to an increase of expression of Mcl-1, a member of the anti-apoptotic family bcl-2, via the Jak/STAT pathway, but with participation of STAT3, whose activation determines the mcl-2 promoter transcription activity [13–15].”
BackgroundThe role of STAT3 in the colorectal cancer therapy
Papierska, K., & Krajka‐Kuźniak, V. (2020) · Journal of Medical Science · doi:10.20883/medical.e427 · Cited by 8
Trécul, A., Morceau, F., Gaigneaux, A., Orsini, M., Chateauvieux, S., Grandjenette, C., Dicato, M. A., & Diederich, M. F. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.023 · Cited by 8
Advances in the Diagnosis and Classification of Chronic Lymphoproliferative Disorders
Hsi, E. D., & Frater, J. L. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7920-6_6 · Cited by 8
Combinatorial approach to identification of tyrphostin inhibitors of cytokine signaling
Gu, L., Zhuang, H., Safina, B. S., Xiao, X., Bradford, W. W., & Rich, B. E. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.022 · Cited by 9
The complex relationship between large granular lymphocyte leukemia and rheumatic disease
Marchand, T., & Lamy, T. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2292758 · Cited by 8
“The implication of STAT3 in LGL leukemia was first described in 2001 [43].”
BackgroundWang, T. T., Yang, J., Dighe, S. A., Schmachtenberg, M. W., Leigh, N. T., Farber, E., Önengüt-Gümüşcü, S., Feith, D. J., Ratan, A., Loughran, T. P., et al. (2020) · Cancers · doi:10.3390/cancers12010126 · Cited by 7
“Dysregulated STAT1, STAT3, and STAT5 signaling is well documented in LGL leukemia [18].”
BackgroundSelf-citationTranscriptional Regulation of Apoptosis
Dudgeon, C., Qiu, W., Sun, Q., Zhang, L., & Yu, J. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-381-7_10 · Cited by 9
IL-15 as a potential target in leukemia
Decot, V., Xiong, Y., & Bensoussan, D. (2015) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s78347 · Cited by 9
“Finally, Epling-Burnette et al demonstrated that STAT3 activation contributed to accumulation of the leukemic LGL clones, as a variety of STAT3 inhibitors come forth to the clinic, suggested that investigation could focus on STAT3 inhibitors in the treatment of LGL leukemia.(77) However, IL-15 can activate many immune…”
Zhou, W. (2006) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 7
Effect of caveolin-1 on Stat3-ptyr705 levels in breast and lung carcinoma cells
Geletu, M., Taha, Z., Arulanandam, R., Mohan, R., Assi, H. H., Castro, M. G., Nabi, I. R., Gunning, P. T., & Raptis, L. H. (2019) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0367 · Cited by 7
HMGN4 plays a key role in STAT3-mediated oncogenesis of triple-negative breast cancer
Mou, J., Xu, X., Wang, F., Kong, W., Chen, J., & Ren, J. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac056 · Cited by 9
Bcl-2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Hu, J., Duan, Z., Yu, G., & Wang, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00010-9 · Cited by 8
Gorodetskiy, V. R., Sidorova, Y. V., Вениаминовна, Б. Б., Александровна, К. Н., Ryzhikova, N. V., & Sudarikov, A. B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1000265 · Cited by 6
“In conclusion, we have described a cohort of patients with various ARDs and expansion of T-LGLs of less than 0.5 × 109/L in the peripheral blood.”
BackgroundInfluentialGorodetskiy, V. R., Sidorova, Y. V., Вениаминовна, Б. Б., Ryzhikova, N. V., Vasilyev, V. I., & Sudarikov, A. B. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/dyi9hd · Cited by 6
“Deregulation of Janus kinase/ signal transducer and activator of transcription nuclear factor kappa β signal pathways, playing an important role in the pathogenesis of both RA (22-25) and T-LGL leukaemia (26, 27), may be responsible for the frequent association of these diseases.”
BackgroundZou, Z., Yin, Y., Lin, J., Hsu, L.-C. J., Brandon, V. L., Yang, F., Jove, R., Jandial, R., Li, G., & Chen, M. Y. (2015) · Journal of neurosurgery · doi:10.3171/2015.3.jns132040 · Cited by 6
Self-citationMolecular Diagnostics of T-Cell Lymphoproliferative Disorders
Bailey, N. G., & Elenitoba‐Johnson, K. S. J. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000016 · Cited by 6
Adan, H., Guy, S., Arulanandam, R., Geletu, M., Daniel, J. M., & Raptis, L. H. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00462-5 · Cited by 6
“Cadherin-11 and Rac are required for survival of Srcexpressing cells Previous results have shown that Stat3 induces anti-apoptotic genes such as bcl-xL, mcl-1, and survivin [4, 30, 31], it downregulates the p53 promoter [3], while it can affect the cellular metabolism through its ser727-phosphorylated form, in a way t…”
BackgroundLiang, C. S., Quesada, A. E., Goswami, M., Johnston, P. K., Brown, R. E., & Jaso, J. M. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.336 · Cited by 6
Metadata
- Authors
- Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., & Loughran, T. P.
- Affiliations
- University of South Florida (US)
- National Taiwan University (TW)
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 351-362
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC199188
- OpenAlex
- W2041204531
- Cited by
- 633
- References
- 60
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 31 · 2019: 22 · 2018: 14 · 2017: 27 · 2016: 15 · 2015: 27 · 2014: 46 · 2013: 31 · 2012: 35
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Moffitt Cancer Center
- National Institutes of Health (5r21ca078724-02)
- National Cancer Institute (R01CA055652, CA-55652, CA78724)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- large granular lymphocyte leukemia, STAT3 signaling, apoptosis, Mcl-1, Fas resistance, AG490, antisense oligonucleotides, Bcl-2 family proteins, v-Src
- MeSH terms
- Cell Line, DNA-Binding Proteins, Enzyme Inhibitors, Gene Expression Regulation, Humans, Leukemia, Neoplasm Proteins, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Trans-Activators, Oncogene Protein pp60(v-src), Apoptosis, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-bcl-2, Dimerization, Tyrphostins, STAT3 Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.